Publications

5491 Results

SWOG S2012: Randomized Phase II/III Trial of First Line Platinum/Etoposide (P/E) with or without Atezolizumab (NSC#783608) in Patients (pts) with Poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)

Authors
D Zhen;E Mayerson;E Chiorean;E Burgess;E Swisher;C Gay;L Byers;I Wistuba;H Mahdi;S Das;J Starr;M Othus;YK Chae;R Kurzrock
Journal / Conference
J Clin Oncol 40, 2022 (suppl 16; abstr TPS4179), poster 155a; ASCO Annual Meeting (June 3-7, 2022, Chicago, IL)
Year
2022
Research Committee(s)
Early Therapeutics and Rare Cancers
Study Number(s)
S2012

EA2201: An ECOG-ACRIN phase II study of neoadjuvant nivolumab plus ipilimumab and short course radiation in MSI-H/dMMR rectal tumors

Authors
K Ciombor;S Hong;C Eng;X Yao;M Thet Cho;YN You;P Das;A Chakravarthy;P O'Dwyer
Journal / Conference
J Clin Oncol 40, 2022 (suppl 16; abstr TPS3644), poster 430A; ASCO Annual Meeting (June 3-7, 2022, Chicago, IL), poster session
Year
2022
Research Committee(s)
Gastrointestinal
Study Number(s)
CTSU/EA2201

Early quality of life (QOL) and symptom analysis from the DREAMseq phase III randomized control trial of combination immunotherapy vs targeted therapy in patients (pts) with BRAF mutant metastatic melanoma (MM) (ECOG-ACRIN EA6134)

Authors
R Jensen;Y Zheng;M Atkins;B Chmielowski;A Tarhini;T-G Truong;D Divar;M O'Rourke;B Curti;J Brell;K Kendra;A Ikeguchi;S Lee;A Potosky;J Wolchok
Journal / Conference
J Clin Oncol 40, 2022 (suppl 16; abstr 9559), poster 152; ASCO Annual Meeting (June 3-7, 2022, Chicago, IL)
Year
2022
Research Committee(s)
Melanoma
Study Number(s)
CTSU/EA6134

A Phase II Study of Biomarker Driven Early Discontinuation of Anti-PD-1 Therapy in Patients with Advanced Melanoma (PET-Stop): ECOG-ACRIN EA6192.

Authors
G Gibney;S Lee;M Atkins;T Wong;J Guerriero;T Marron;G Cohen;T-G Truong;R Carvajal;B Snyder;M Farwell;J Kirkwood;J Wolchok
Journal / Conference
J Clin Oncol 40, 2022 (suppl 16; abstr TPS9591), poster 183A; ASCO Annual Meeting (June 3-7, 2022, Chicago, IL)
Year
2022
Research Committee(s)
Melanoma
Study Number(s)
EA6192

EA-2186: A randomized phase II Study of Gemcitabine and Nab-Paclitaxel Compared with 5- Fluorouracil, Leucovorin, and Liposomal Irinotecan in older patients with treatment naïve metastatic pancreatic cancer (GIANT): Trials in Progress

Authors
E Dotan;P Catalano;L Lenchik;R Boutin;X Yao;C Gatsonis;D Zhen;D Li;L Wagner;M Simon;T Wong;P O'Dwyer
Journal / Conference
J Clin Oncol 40, 2022 (suppl 16; abstr TPS4185), poster 157B; ASCO Annual Meeting (June 3-7, 2022, Chicago, IL)
Year
2022
Research Committee(s)
Gastrointestinal
Study Number(s)
CTSU/EA2186

A Phase II/III Trial of Chemotherapy + Cetuximab vs. Chemotherapy + Bevacizumab vs. Atezolizumab + Bevacizumab Following Progression on Immune Checkpoint Inhibition in Recurrent/Metastatic Head and Neck Cancers: ECOG-ACRIN EA3202

Authors
A Bhatia;Y Flamand;J Johnson;J Ishizuka;F Duan;M Tang;V Karivedu;R Subramaniam;B Burtness
Journal / Conference
J Clin Oncol 40, 2022 (suppl 16; abstr TPS6098), poster 89A; ASCO Annual Meeting (June 3-7, 2022, Chicago, IL)
Year
2022
Research Committee(s)
Early Therapeutics and Rare Cancers

A Phase III Double Blinded Study of Early Intervention After RADICAl ProstaTEctomy With Androgen Deprivation Therapy With Darolutamide vs. Placebo in Men at Highest Risk of Prostate Cancer Metastasis by Genomic Stratification (ERADICATE)

Authors
A Morgans;Y Chen;A Ferrari;P Tran;E Schaeffer;D Shevrin;R Szmulewitz;T Boike;T Dorff;G Liu;L Wagner;M Carducci
Journal / Conference
J Clin Oncol 40, 2022 (suppl 16; abstr TPS4617), poster #98B; ASCO Annual Meeting (June 3-7, 2022, Chicago, IL)
Year
2022
Research Committee(s)
Genitourinary

EA8185: Phase 2 Study of Bladder-SparIng ChemoradiatioN (chemoRT) with Durvalumab in Clinical Stage III, Node PosItive URothElial Carcinoma (INSPIRE), an ECOG-ACRIN/NRG Collaboration

Authors
M Joshi;S Kim;A Solanki;D Miyamoto;D Degraff;J Zou;J Meeks;T Mitin;S Collins;E Trabulsi;N Hahn;J Efstathiou;M Carducci
Journal / Conference
J Clin Oncol 40, 2022 (suppl 16; abstr TPS4617), poster 98B; ASCO Annual Meeting (June 3-7, 2022, Chicago, IL)
Year
2022
Research Committee(s)
Genitourinary
Study Number(s)
CTSU/EA8185

Improving Patient Advocacy in NCI Scientific Steering Committees and Task Forces

Authors
R Bangs;J Lynn;E Obot;S Osborne;K Norris
Journal / Conference
Journal of the National Cancer Institute Aug 8;114(8):1059-1064
Year
2022
Research Committee(s)
Cancer Care Delivery
PMID
PMID35552713
PMC
PMC9360467

Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced Non-Small Cell Lung Cancer Previously Treated with Immunotherapy—Lung-MAP S1800A

Authors
K Reckamp;M Redman;K Dragnev;L Villaruz;B Faller;T Al Baghdadi;S Hines;L Everhart;L Highleyman;K Minichiello;V Papadimitrakopoulou;J Neal;S Waqar;S Waqar;J Patel;J Gray;D Gandara;K Kelly;R Herbst
Journal / Conference
Journal of Clinical Oncology Jul 20;40(21):2295-2306
Year
2022
Research Committee(s)
Lung
PMID
PMID35658002
PMC
PMC9287284
Study Number(s)
S1800A